Enobia Announces Positive Clinical Results With ENB-0040, A Bone Targeted Enzyme Replacement Therapy For Hypophosphatasia

Enobia Pharma announced positive data from a clinical study of ENB-0040, a bone targeted enzyme replacement therapy, under investigation for the treatment of hypophosphatasia (HPP).